Candriam Luxembourg S.C.A. boosted its holdings in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 94.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 59,100 shares of the biotechnology company’s stock after purchasing an additional 28,700 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.16% of Spark Therapeutics worth $3,224,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of ONCE. Millennium Management LLC purchased a new position in Spark Therapeutics during the 1st quarter worth $1,578,000. Amalgamated Bank grew its position in Spark Therapeutics by 29.7% during the 2nd quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 1,100 shares during the last quarter. Aperio Group LLC grew its position in Spark Therapeutics by 23.5% during the 2nd quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock worth $459,000 after purchasing an additional 1,056 shares during the last quarter. Alps Advisors Inc. grew its position in Spark Therapeutics by 8.2% during the 2nd quarter. Alps Advisors Inc. now owns 53,708 shares of the biotechnology company’s stock worth $4,445,000 after purchasing an additional 4,076 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its position in Spark Therapeutics by 21.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 32,300 shares of the biotechnology company’s stock worth $2,673,000 after purchasing an additional 5,800 shares during the last quarter.

Shares of NASDAQ:ONCE opened at $38.78 on Wednesday. The stock has a market capitalization of $1.48 billion, a PE ratio of -5.08 and a beta of 2.27. The company has a current ratio of 10.71, a quick ratio of 10.36 and a debt-to-equity ratio of 0.09. Spark Therapeutics Inc has a fifty-two week low of $35.63 and a fifty-two week high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.18%. The company had revenue of $10.70 million during the quarter, compared to analyst estimates of $27.44 million. During the same quarter last year, the business earned ($1.90) EPS. The firm’s revenue for the quarter was up 463.2% on a year-over-year basis. On average, equities analysts predict that Spark Therapeutics Inc will post -1.44 earnings per share for the current fiscal year.

Several research analysts have issued reports on the stock. Credit Suisse Group raised shares of Spark Therapeutics from an “underperform” rating to a “neutral” rating and lowered their price objective for the stock from $48.00 to $44.00 in a research report on Friday, November 16th. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 8th. Mizuho lowered their price objective on shares of Spark Therapeutics to $62.00 and set a “buy” rating on the stock in a research report on Wednesday, November 7th. BMO Capital Markets lowered their target price on shares of Spark Therapeutics to $48.00 and set a “market perform” rating on the stock in a report on Wednesday, November 7th. Finally, B. Riley raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $68.00 to $71.00 in a report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the company. Spark Therapeutics has an average rating of “Hold” and an average price target of $65.95.

WARNING: “Candriam Luxembourg S.C.A. Raises Holdings in Spark Therapeutics Inc (ONCE)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/11/21/candriam-luxembourg-s-c-a-raises-holdings-in-spark-therapeutics-inc-once.html.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Article: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.